Doxycycline Controlled-Release Capsule Food Effect

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The commercially available doxycycline capsules for rosacea treatment exhibit significant food effects, requiring patients to take the medication on an empty stomach, which complicates patient compliance and convenience.

Innovation Solution

A once-daily pharmaceutical composition of doxycycline combined with a controlled-release polymer and pharmaceutically acceptable excipients, designed to minimize food effects, allowing for administration without regard to meals, comprising an immediate-release and controlled-release portion to maintain therapeutic levels with reduced dosages.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If doxycycline is administered in immediate-release capsules, then therapeutic effect is achieved, but food effect significantly reduces drug absorption (Cmax decreases by 45% and AUC0-t decreases by 22%)

Engineering Contradiction:
Improvetherapeutic effectVSAvoidfood effect
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The doxycycline capsule is divided into two distinct components: an immediate-release portion (30 mg) and a delayed-release portion (10 mg). This segmentation allows the immediate-release portion to provide rapid therapeutic effect while the delayed-release portion maintains therapeutic levels, thereby reducing the overall impact of food on drug absorption and enabling more flexible dosing relative to meals.

Inventive Principle:
Principle #1Segmentation

2Reliability

If doxycycline is taken on an empty stomach to avoid food effect, then drug absorption is improved, but patient compliance and convenience are reduced

Engineering Contradiction:
Improvedrug absorptionVSAvoidpatient compliance
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

By segmenting the capsule into immediate-release and delayed-release portions, the invention allows patients to take the medication with or without food. The immediate-release portion ensures adequate absorption even when taken with food, while the delayed-release portion provides sustained therapeutic levels, thereby improving patient compliance without sacrificing drug absorption efficacy.

Inventive Principle:
Principle #1Segmentation

3Reliability

If doxycycline dosage is increased to compensate for food effect, then therapeutic levels are maintained, but side effects and toxicity risk increase

Engineering Contradiction:
Improvetherapeutic levelsVSAvoidside effects
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The segmented capsule design with immediate-release and delayed-release portions allows for optimized dosing that maintains therapeutic levels without requiring excessive dosages. The immediate-release portion provides rapid absorption to reach therapeutic levels quickly, while the delayed-release portion maintains these levels over time, avoiding the need for higher doses that would increase side effects and toxicity risk.

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition achieves reduced food effects, with Cmax and AUC0-t decreases of less than 40% and 20% respectively, enabling patients to take the medication at any time, improving compliance and maintaining therapeutic efficacy.

Implementation Method 1

A first aspect of the invention provides a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients

Methodology Applied
Scientific EffectControlled-release:

Data Source

PatentUS9561242B2Doxycycline composition
Publication Date: 2017.02.07 SUN PHARMACEUTICAL INDUSTRIES LTD

AI summary

The present invention relates to a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients. The invention further provides a method of treatment of rosacea by administering such pharmaceutical composition. A process of preparing such pharmaceutical composition is also provided.